PROSTATA BEZI SARATONIDA BEMORLARDA SIYDIK PUFAGI GIPERFAOLLIGI BILAN PROSTATA HAJMI VA PROSTATASPESIFIK ANTIGEN DARAJASINING QIYOSIY TAHLILI
##article.subject##:
Prostata bezi saratoni, prostate spesifik antigen, transrektal ultratovush biopsiyasi, androgenlardan mahrum qilish terapiyasi##article.abstract##
Prostata bezi saratonining oldini olish bilan bog‘liq holda, Amerika profilaktik xizmatlar bo‘yicha ishchi guruhi (USPSTF -United States Preventive Services Taskforce) 55 yoshdan 69 yoshgacha bo‘lgan erkaklar uchun prostataspesifik antigen (PSA) bo‘yicha skrining o‘tkazishni tavsiya qiladi, chunki bu usul saraton tufayli o‘lim holatlarini kamaytirishda muayyan foyda berishi mumkin deb hisoblanadi. Biroq, 70 yoshdan katta erkaklar uchun skrining samaradorligi kamroq ishonarli ko‘rinadi. Prostata bezi saratoni odatda barmoq orqali rektal tekshiruv va qonda prostataspesifik antigen darajasini tahlil qilish orqali aniqlanadi, bu protseduradan keyin transrektal ultratovush nazorati ostida biopsiya o‘tkaziladi. Tadqiqotlar shuni ko‘rsatdiki, androgenlardan mahrum qilish terapiyasi (ADT) o‘ziyoq faol kuzatuv bilan solishtirganda siydik tutolmaslik xavfining oshishi bilan bog‘liq. Baʼzi Osiyo mamlakatlarida olib borilgan prospektiv tadqiqotlar prostata saratoniga chalingan bemorlarda androgenlardan mahrum qilish terapiyasi qo‘llanilganda pastki siydik yo‘llari simptomlarining yaxshilanganini qayd etgan. Bu tadqiqotlarda asosiy e’tibor prostata hajmining kamayishi va urofloometriya ko‘rsatkichlarining yaxshilanishiga qaratilgan bo‘lgan. Xususan, prostataspesifik antigen darajasi va prostata hajmining kamayishi terapiya ijobiy natija berayotganidan dalolat beradi, ayniqsa davolashga kompleks yondashuv qo‘llanilgan guruhlarda bu o‘zgarish yaqqol seziladi.
Библиографические ссылки
Kappen S, de Bock GH, Sirri E, Vohmann C, Kieschke J, Winter A. Differences in Prostate Cancer Incidence and Mortality in Lower Saxony (Germany) and Groningen Province (Netherlands): Potential Impact of Prostate-Specific Antigen Testing. Front Oncol. 2021 May 28;11:681006.
Belkahla S, Nahvi I, Biswas S, Nahvi I, Ben Amor N. Advances and development of prostate cancer, treatment, and strategies: A systemic review. Front Cell Dev Biol. 2022 Sep 9;10:991330.
Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019 Apr;10(2):63-89. doi: 10.14740/wjon1191. Epub 2019 Apr 20. PMID: 31068988; PMCID: PMC6497009.
Descotes JL. Diagnosis of prostate cancer. Asian J Urol. 2019 Apr;6(2):129-136.
Sigg S, Lehner F, Keller EX, Saba K, Moch H, Sulser T, Eberli D, Mortezavi A. Outcomes of robot-assisted laparoscopic extended pelvic lymph node dissection for prostate Cancer. BMC Urol. 2024 Jan 29;24(1):24.
Baroni RH. MRI should be routine for all patients with localized prostate cancer? Opinion: Yes. Int Braz J Urol. 2016 Nov-Dec;42(6):1062-1064.
Sprute K, Kramer V, Koerber SA, Meneses M, Fernandez R, Soza-Ried C, Eiber M, Weber WA, Rauscher I, Rahbar K, Schaefers M, Watabe T, Uemura M, Naka S, Nonomura N, Hatazawa J, Schwab C, Schütz V, Hohenfellner M, Holland-Letz T, Debus J, Kratochwil C, Amaral H, Choyke PL, Haberkorn U, Sandoval C, Giesel FL. Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. J Nucl Med. 2021 Feb;62(2):208-213.
Li JR, Wang SS, Chen CS, Cheng CL, Hung SC, Lin CH, Chiu KY. Conventional androgen deprivation therapy is associated with an increased risk of cardiovascular disease in advanced prostate cancer, a nationwide population-based study. PLoS One. 2022 Jun 28;17(6):e0270292.
Akpayak IC, Shuaibu SI, Ofoha CG, Dakum NK, Ramyil VM, Onowa VE, Agbo CA, Nabasu LE, Galam ZZ. Lower urinary tract symptoms in patients with advanced prostate cancer: What are the outcomes of androgen deprivation therapy? Niger Postgrad Med J. 2020 Jan-Mar;27(1):49-53.
Alimjanovich , R. Z., Maxammatkulovich , R. N., & Khikmatovich , K. K. (2022). Age Features of the Prevalence of Prostate Cancer in Uzbekistan. Central Asian Journal of Medical and Natural Science, 3(5), 154-157. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/1062
Rizaev Jasur , Rakhimov Nodir , Kodyrov Khamidullo , Shakhanova Shakhnoza . Study of prostate cancer death by regions of the republic of Uzbekistan.Journal of Biomedicine and Practice. 2022, vol . 7, issue 5, pp.202-210
Rizaev AND . A. , Rakhimov N. M. , Kadirov X . X . RESPUBLIK A NING VILOYATL A R KESIMID A PROST A T A BEZI S A R A TONINI K A S A LL A NISH KO'RS A TGICHINI O'RG A NISH // MAGAZINE REPRODUCTIVE HEALTH AND URO - NEPHROLOGICAL RESEARCH . – 2022. – T. 3. – No. 3.
Shavkatovna, S. S., Makhammatkulovich, R. N., & Ugli, M. S. T. (2024). Aspects of sarcopenia syndrome in oncological practice: Diagnosis and treatment. The American Journal of Medical Sciences and Pharmaceutical Research, 6(2).
Shakhanova, S. S., & Rakhimov, N. M. (2025). The role of troponin and IL-6 in immunological assessment of sarcopenia in oncological patients. Central Asian Journal of Medical and Natural Science, 6(3), 1229–1233.
Rakhimov, N. M., & Shakhanova, S. Sh. (2025). Omega-3 supplementation in combination therapy for anorexia syndrome in metastatic breast cancer. American Journal of Medicine and Medical Sciences.
